Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Sage TherapeuticsHutchison China MediTechI-MabReata PharmaceuticalsFibroGen
SymbolNASDAQ:SAGENASDAQ:HCMNASDAQ:IMABNASDAQ:RETANASDAQ:FGEN
Price Information
Current Price$72.92$29.31$55.63$90.85$20.32
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.41.41.41.41.8
Analysis Score3.33.53.53.54.1
Community Score3.12.73.32.62.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.81.7
Earnings & Valuation Score0.60.60.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$86.69$40.00$70.00$237.43$45.83
% Upside from Price Target18.88% upside36.47% upside25.83% upside161.34% upside125.56% upside
Trade Information
Market Cap$4.29 billion$4.22 billion$4.09 billion$3.23 billion$1.87 billion
Beta2.231.12N/A1.571.59
Average Volume493,373233,153359,016287,7481,490,590
Sales & Book Value
Annual Revenue$6.87 million$204.89 million$4.31 million$26.52 million$256.58 million
Price / Sales619.6820.83928.63124.017.29
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$18.23 per share$2.35 per share$3.34 per share$7.74 per share$6.14 per share
Price / Book4.0012.4716.6611.743.31
Profitability
Net Income$-680,240,000.00$-106,020,000.00$-208,560,000.00$-290,170,000.00$-76,970,000.00
EPS($13.38)($0.80)($28.90)($9.54)($0.89)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-7,706.84%N/AN/A-4,340.72%-191.78%
Return on Equity (ROE)-63.81%N/AN/A-163.42%-48.19%
Return on Assets (ROA)-56.64%N/AN/A-56.49%-27.72%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.07%N/AN/AN/A
Current Ratio11.71%3.14%N/A12.98%6.23%
Quick Ratio11.71%3.01%N/A12.98%6.13%
Ownership Information
Institutional Ownership PercentageN/A33.45%16.64%64.30%75.05%
Insider Ownership Percentage4.80%N/AN/A31.70%3.39%
Miscellaneous
Employees2981,280185261599
Shares Outstanding58.38 million145.62 million71.95 million36.20 million92.07 million
Next Earnings Date5/4/2021 (Confirmed)N/AN/A5/10/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableOptionable
SourceHeadline
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAN, CS, DOX and FGENFILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CAN, CS, DOX and FGEN
finance.yahoo.com - April 21 at 12:03 AM
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Yahoo FinanceKessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Yahoo Finance
finance.yahoo.com - April 20 at 7:02 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Announces Filing of Securities Fraud Class Action - GlobeNewswireHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Announces Filing of Securities Fraud Class Action - GlobeNewswire
globenewswire.com - April 20 at 7:02 PM
FIBROGEN INVESTOR ALERT: Shareholder Lawsuit Filed - Yahoo FinanceFIBROGEN INVESTOR ALERT: Shareholder Lawsuit Filed - Yahoo Finance
finance.yahoo.com - April 20 at 7:02 PM
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
finance.yahoo.com - April 20 at 7:02 PM
FibroGen (NASDAQ:FGEN) Shares Up 5.3%FibroGen (NASDAQ:FGEN) Shares Up 5.3%
americanbankingnews.com - April 20 at 1:40 PM
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN) - Business WireGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN) - Business Wire
businesswire.com - April 20 at 8:55 AM
FGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Fibrogen, Inc. ShareholdersFGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Fibrogen, Inc. Shareholders
finance.yahoo.com - April 20 at 8:55 AM
Rosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN - Yahoo FinanceRosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN - Yahoo Finance
finance.yahoo.com - April 19 at 10:22 PM
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN - Yahoo FinanceSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN - Yahoo Finance
finance.yahoo.com - April 19 at 10:22 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established - Yahoo FinanceHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established - Yahoo Finance
finance.yahoo.com - April 19 at 10:22 PM
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGENSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
finance.yahoo.com - April 19 at 10:22 PM
Lawsuit filed for Investors in shares of FibroGen, Inc. (NASDAQ: FGEN) - openPRLawsuit filed for Investors in shares of FibroGen, Inc. (NASDAQ: FGEN) - openPR
openpr.com - April 19 at 5:22 PM
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN) - Yahoo FinanceGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN) - Yahoo Finance
finance.yahoo.com - April 19 at 5:22 PM
Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action Lawsuit - The ReporterKessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action Lawsuit - The Reporter
thereporteronline.com - April 19 at 5:22 PM
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
finance.yahoo.com - April 19 at 5:22 PM
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 19 at 5:22 PM
Kessler Topaz Meltzer & Check, LLP:  Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action LawsuitKessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action Lawsuit
finance.yahoo.com - April 19 at 5:22 PM
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited ShareholdersFGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
finance.yahoo.com - April 19 at 5:22 PM
Rosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGENRosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN
finance.yahoo.com - April 19 at 5:22 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN - Yahoo FinanceSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN - Yahoo Finance
finance.yahoo.com - April 19 at 12:22 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established - KPVI News 6HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established - KPVI News 6
kpvi.com - April 19 at 12:22 PM
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm - Business WireFGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire
businesswire.com - April 19 at 12:22 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline EstablishedHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Investor Deadline Established
finance.yahoo.com - April 19 at 12:22 PM
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the FirmFGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
finance.yahoo.com - April 19 at 12:22 PM
FibroGen (NASDAQ:FGEN) Lifted to Neutral at JPMorgan Chase & Co.FibroGen (NASDAQ:FGEN) Lifted to Neutral at JPMorgan Chase & Co.
marketbeat.com - April 7 at 10:12 AM
FibroGen (NASDAQ:FGEN) Raised to "Buy" at Bank of AmericaFibroGen (NASDAQ:FGEN) Raised to "Buy" at Bank of America
marketbeat.com - March 31 at 7:42 AM
DateCompanyBrokerageAction
4/19/2021Sage TherapeuticsMorgan StanleyLower Price Target
4/12/2021Sage TherapeuticsMizuhoReiterated Rating
4/7/2021Sage TherapeuticsPiper SandlerInitiated Coverage
3/3/2021Sage TherapeuticsOppenheimerBoost Price Target
2/25/2021Sage TherapeuticsHC WainwrightBoost Price Target
2/1/2021Sage TherapeuticsRaymond JamesInitiated Coverage
1/22/2021Sage TherapeuticsBMO Capital MarketsDowngrade
1/19/2021Sage TherapeuticsWedbushBoost Price Target
1/4/2021Sage TherapeuticsGuggenheimUpgrade
1/4/2021Sage TherapeuticsRoyal Bank of CanadaDowngrade
12/4/2020Sage TherapeuticsWilliam BlairReiterated Rating
12/1/2020Sage TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
12/1/2020Sage TherapeuticsTruistBoost Price Target
12/1/2020Sage TherapeuticsSmith Barney CitigroupLower Price Target
10/2/2020Hutchison China MediTechDeutsche Bank AktiengesellschaftInitiated Coverage
3/12/2020Hutchison China MediTechCantor FitzgeraldInitiated Coverage
2/20/2020Hutchison China MediTechThe Goldman Sachs GroupInitiated Coverage
11/19/2019Hutchison China MediTechCLSAInitiated Coverage
10/23/2019Hutchison China MediTechBank of AmericaInitiated Coverage
7/5/2019Hutchison China MediTechMacquarieInitiated Coverage
3/27/2019Hutchison China MediTechHSBCInitiated Coverage
3/22/2021I-MabNeedham & Company LLCInitiated Coverage
2/13/2020I-MabCICC ResearchInitiated Coverage
2/12/2020I-MabChina Renaissance SecuritiesInitiated Coverage
2/11/2020I-MabJefferies Financial GroupInitiated Coverage
8/10/2020Reata PharmaceuticalsStifel NicolausLower Price Target
6/16/2020Reata PharmaceuticalsBTIG ResearchInitiated Coverage
6/12/2020Reata PharmaceuticalsRobert W. BairdReiterated Rating
11/13/2019Reata PharmaceuticalsNational SecuritiesDowngrade
4/13/2021FibroGenJPMorgan Chase & Co.Upgrade
4/13/2021FibroGenSVB LeerinkLower Price Target
5/1/2020FibroGenCowenInitiated Coverage
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.